0001104659-23-077076.txt : 20230630 0001104659-23-077076.hdr.sgml : 20230630 20230630160531 ACCESSION NUMBER: 0001104659-23-077076 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230629 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 231061688 BUSINESS ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 tm2320339d1_8k.htm FORM 8-K
0001446847 false 0001446847 2023-06-29 2023-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported): June 29, 2023

 

 

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-34620   04-3404176
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File No.)   Identification No.)

 

100 Summer Street, Suite 2300

Boston, Massachusetts 02110

(Address of principal executive offices)

 

(617) 621-7722

Registrant’s telephone number, including area code:

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A Common Stock, $0.001 par value per share IRWD Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

 

 

Item 2.01Completion of Acquisition or Disposition of Assets.

 

On June 29, 2023, Ironwood Pharmaceuticals, Inc., a Delaware corporation (“Ironwood”), announced the expiration of its cash tender offer (the “Offer”) to acquire all of the outstanding registered ordinary shares, nominal value of CHF 0.05 per share (the “Shares”) of VectivBio Holding AG, a corporation limited by shares organized under the laws of Switzerland (“VectivBio”), at a price per share equal to $17.00, net to the shareholders of VectivBio in cash, without interest and subject to any applicable withholding taxes, pursuant to that certain Transaction Agreement (the “Transaction Agreement”), dated May 21, 2023, by and between Ironwood, and VectivBio.

 

The Offer and any withdrawal rights in connection therewith expired as scheduled at one minute after 11:59 P.M., Eastern Time, on June 28, 2023 (the “Expiration Date”). Ironwood has been advised that, as of the Expiration Date, 59,287,753 Shares have been validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 94.40% of the Shares outstanding (not including 2,007,310 Shares delivered pursuant to guaranteed delivery procedures, representing approximately 3.20% of the Shares outstanding). The number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition (as defined in the Transaction Agreement). As all conditions to the Offer have been satisfied or waived, Ironwood has accepted for payment (such time, the “Acceptance Time”) all Shares that were validly tendered and not validly withdrawn in accordance with the terms of the Offer.

 

At the Acceptance Time, each option to purchase Shares (each, a “VectivBio Stock Option”), whether vested or unvested, that was outstanding and unexercised immediately prior to the Acceptance Time was cancelled in exchange for an amount in cash (without interest, and subject to deduction for any applicable withholding taxes) equal to the product, rounded down to the nearest cent, of (i) the excess, if any, of the Offer Price over the exercise price per Share of such VectivBio Stock Option and (ii) the number of Shares subject to such VectivBio Stock Option. If the exercise price per Share of any VectivBio Stock Option was equal to or greater than the Offer Price, such VectivBio Stock Option was automatically cancelled for no consideration with no further force or effect. Additionally, at the Acceptance Time, (i) each Share subject to a repurchase option of VectivBio (each, a “VectivBio Restricted Share”) that was outstanding immediately prior to the Acceptance Time automatically became fully vested and was treated the same as all other Shares in accordance with the terms and conditions of the Offer (subject to deduction for any applicable withholding taxes), and (ii) each restricted share unit award covering Shares that vested based solely on the passage of time (each, a “VectivBio RSU Award”) that was outstanding immediately prior to the Acceptance Time automatically became fully vested and was cancelled in exchange for an amount in cash (without interest, and subject to deduction for any applicable withholding taxes) equal to the product, rounded down to the nearest cent, of (A) the Offer Price and (B) the number of Shares subject to such VectivBio RSU Award as of immediately prior to the Acceptance Time.

 

The aggregate consideration paid by Ironwood to acquire the Shares accepted for payment (including the amounts payable to the holders of VectivBio Restricted Shares, VectivBio Stock Options and VectivBio RSU Awards as described above) was approximately $1.15 billion. Ironwood obtained the funds necessary to fund the acquisition through proceeds from the borrowings under the Revolving Credit Agreement (as defined below), cash on hand and cash of VectivBio.

 

Ironwood intends that, in accordance with the laws of Switzerland and a merger agreement expected to be entered into between Ironwood Pharmaceuticals GmbH, a limited liability company organized under the laws of Switzerland and a subsidiary of Ironwood (“Merger Sub”), and VectivBio, Merger Sub and VectivBio will consummate a statutory squeeze-out merger pursuant to which VectivBio will be merged with Merger Sub, and Merger Sub will continue as the surviving entity (the “Merger”). At the effective time of the Merger, each Share (other than Shares held by VectivBio or any of its subsidiaries immediately prior to the Acceptance Time) that was not validly tendered and accepted pursuant to the Offer or acquired by Ironwood after the Acceptance Time will thereupon be cancelled and converted into the right to receive the Offer Price. To the extent permitted under applicable law and stock exchange regulations, Ironwood intends to delist the Shares from Nasdaq and provided that the criteria for deregistration are met, Ironwood intends to cause VectivBio to make a filing with the Securities and Exchange Commission requesting that VectivBio’s reporting obligations under the Securities Exchange Act of 1934, as amended, be terminated.

 

 

 

 

The description of the Transaction Agreement contained in this Item 2.01 (including the description in the immediately preceding paragraph) does not purport to be complete and is subject to and qualified in its entirety by reference to the Transaction Agreement, which was filed as Exhibit 2.1 to Ironwood’s Current Report on Form 8-K, filed on May 22, 2023, the terms of which are incorporated herein by reference.

 

Item 2.03Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

 

As previously disclosed on Ironwood’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023, Ironwood entered into a credit agreement (the “Revolving Credit Agreement”) with Wells Fargo Bank, N.A., as administrative agent, the lenders and other agents party thereto. On June 29, 2023, Ironwood borrowed $400,000,000 under the Revolving Credit Agreement to fund a portion of the consideration paid to purchase the Shares in connection with the Offer.

 

The description of the Revolving Credit Agreement contained in this Item 2.03 (including the description in the immediately preceding paragraph) does not purport to be complete and is subject to and qualified in its entirety by reference to the Revolving Credit Agreement, which was filed as Exhibit 10.1 to Ironwood’s Current Report on Form 8-K, filed on May 22, 2023, the terms of which are incorporated herein by reference.

 

Item 8.01Other Events.

 

On June 29, 2023, Ironwood and VectivBio issued a joint press release announcing the expiration and results of the Offer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired.

 

To be filed by amendment not later than 71 calendar days after the date this Current Report is required to be filed.

 

(b) Pro Forma Financial Information.

 

To be filed by amendment not later than 71 calendar days after the date this Current Report is required to be filed.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Joint Press Release, dated June 29, 2023, of Ironwood Pharmaceuticals, Inc. and VectivBio Holding AG
     
104   Cover page Interactive Data File (embedded within the Inline XBRL document)  

 

 

 

 

Cautionary Statement Regarding Forward-Looking Statements

 

Certain statements in this communication may constitute “forward-looking statements,” including those regarding the expected nature, timing and benefits of the transaction. Forward-looking statements may be typically identified by such words as “may,” “will,” “could,” “should,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause Ironwood’s or VectivBio’s actual results to differ materially from the expectations expressed in the forward-looking statements. Although Ironwood and VectivBio believe that the expectations reflected in the forward-looking statements are reasonable, any or all of such forward-looking statements may prove to be incorrect. Consequently, no forward-looking statements may be guaranteed and there can be no assurance that the actual results or developments anticipated by such forward looking statements will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Ironwood, VectivBio or their respective businesses or operations.

 

Factors which could cause actual results to differ from those projected or contemplated in any such forward-looking statements include, but are not limited to, the following factors: (1) litigation relating to the transaction; (2) uncertainties as to the timing of the consummation of the Merger and the ability of each of VectivBio and Ironwood to consummate the Merger; (3) risks that the completion of the Offer or the Merger disrupts the current plans and operations of VectivBio or Ironwood; (4) the ability of Ironwood and/or VectivBio to retain and hire key personnel; (5) competitive responses to the completion of the Offer and/or the Merger; (6) unexpected costs, charges or expenses resulting from the completion of the Offer or the Merger; (7) potential adverse reactions or changes to business relationships resulting from the completion of the Offer and/or the Merger; (8) the prospects, including clinical development, regulatory approvals, and commercial potential of apraglutide; (9) Ironwood’s ability to achieve the growth prospects and synergies expected from the transaction, as well as delays, challenges and expenses associated with integrating VectivBio with its existing businesses; and (10) legislative, regulatory and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in VectivBio’s Annual Report on Form 20-F for the year ended December 31, 2022, the risk factors included in Ironwood’s Annual Report on Form 10-K for the year ended December 31, 2022 and Ironwood’s other filings with the SEC (which may be obtained for free at the SEC’s website at http://www.sec.gov). VectivBio and Ironwood can give no assurance that the conditions to the transaction will be satisfied. Neither VectivBio nor Ironwood undertakes any intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 30, 2023

Ironwood Pharmaceuticals, Inc.
     
  By: /s/ Sravan K. Emany
   

Name: Sravan K. Emany

Title: Senior Vice President, Chief Financial Officer

     

 

 

 

EX-99.1 2 tm2320339d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

FOR IMMEDIATE RELEASE

 

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares

 

BOSTON and BASEL, Switzerland – June 29, 2023 – Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the “Shares”) for $17.00 per share in cash (the “Tender Offer”).

 

The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments to tender 2,007,310 additional Shares under the guaranteed delivery procedures described in the offer, representing in the aggregate approximately 97.60 percent of the outstanding Shares. Ironwood has accepted for payment and will promptly pay for all Shares that have been validly tendered and not validly withdrawn in accordance with the terms of the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 31, 2023, as amended. Effective immediately following the completion of the Tender Offer, the current directors of VectivBio were replaced with those Ironwood appointed directors as approved by the VectivBio shareholders at the extraordinary general meeting of shareholders held on June 26, 2023.

 

As previously announced, Ironwood intends to cause VectivBio to voluntarily delist its shares from Nasdaq and intends to effect a squeeze-out merger under Swiss law to acquire all remaining outstanding Shares.

 

The Depositary & Paying Agent for the Tender Offer is Computershare Trust Company, N.A. The Information Agent for the Tender Offer is Innisfree M&A Incorporated. The Tender Offer materials may be obtained at no charge by directing a request by mail to Innisfree M&A Incorporated or by calling toll free at (877) 750-0537 and may also be obtained at no charge at the website maintained by the SEC at www.sec.gov.

 

For further information, contact:

 

Ironwood:

 

Media:

Beth Calitri, 978-417-2031

bcalitri@ironwoodpharma.com

 

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com

 

Matt Roache, 617-621-8395

mroache@ironwoodpharma.com

 

 

 

 

VectivBio:

 

Investors:

Patrick Malloy, 847-987-4878

Patrick.Malloy@VectivBio.com

 

About Ironwood

 

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). In June 2023, the U.S. Food and Drug Administration also approved LINZESS for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

 

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

 

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

 

About VectivBio

 

VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).

 

VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (CoA). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

 

 

 

 

Cautionary Statement Regarding Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements”. Forward-looking statements may be typically identified by such words as “may,” “will,” “could,” “should,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause our actual results to differ materially from the expectations expressed in the forward-looking statements. Although Ironwood and VectivBio believe that the expectations reflected in the forward-looking statements are reasonable, any or all of such forward-looking statements may prove to be incorrect. Consequently, no forward-looking statements may be guaranteed and there can be no assurance that the actual results or developments anticipated by such forward looking statements will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Ironwood, VectivBio or their respective businesses or operations.

 

Factors which could cause actual results to differ from those projected or contemplated in any such forward-looking statements include, but are not limited to, the following factors: (1) litigation relating to the transaction; (2) uncertainties as to the timing of the consummation of the squeeze out transaction and the ability of each of VectivBio and Ironwood to consummate the squeeze out transaction; (3) risks that the completion of the Tender Offer or the squeeze-out transaction disrupts the current plans and operations of VectivBio or Ironwood; (4) the ability of Ironwood and/or VectivBio to retain and hire key personnel; (5) competitive responses to the completion of the Tender Offer and/or the squeeze-out transaction; (6) unexpected costs, charges or expenses resulting from the completion of the Tender Offer or the squeeze-out transaction; (7) potential adverse reactions or changes to business relationships resulting from the completion of the Tender Offer and/or the squeeze-out transaction; (8) the prospects, including clinical development, regulatory approvals, and commercial potential of apraglutide; (9) Ironwood’s ability to achieve the growth prospects and synergies expected from the transaction, as well as delays, challenges and expenses associated with integrating VectivBio with its existing businesses; and (10) legislative, regulatory and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in VectivBio’s Annual Report on Form 20-F for the year ended December 31, 2022, the risk factors included in Ironwood’s Annual Report on Form 10-K for the year ended December 31, 2022 and Ironwood’s other filings with the SEC (which may be obtained for free at the SEC’s website at http://www.sec.gov). VectivBio and Ironwood can give no assurance that the conditions to the transaction will be satisfied. Neither VectivBio nor Ironwood undertakes any intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

###

 

 

 

GRAPHIC 3 tm2320339d1_ex99-1ima001.jpg GRAPHIC begin 644 tm2320339d1_ex99-1ima001.jpg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end EX-101.SCH 4 irwd-20230629.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 irwd-20230629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 irwd-20230629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 29, 2023
Entity File Number 001-34620
Entity Registrant Name IRONWOOD PHARMACEUTICALS, INC.
Entity Central Index Key 0001446847
Entity Tax Identification Number 04-3404176
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Summer Street
Entity Address, Address Line Two Suite 2300
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 617
Local Phone Number 621-7722
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.001 par value per share
Trading Symbol IRWD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2320339d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001446847 2023-06-29 2023-06-29 iso4217:USD shares iso4217:USD shares 0001446847 false 8-K 2023-06-29 IRONWOOD PHARMACEUTICALS, INC. DE 001-34620 04-3404176 100 Summer Street Suite 2300 Boston MA 02110 617 621-7722 false false false false Class A Common Stock, $0.001 par value per share IRWD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ironwoodpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2320339d1_8k.htm irwd-20230629.xsd irwd-20230629_lab.xml irwd-20230629_pre.xml tm2320339d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2320339d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2320339d1_8k.htm" ] }, "labelLink": { "local": [ "irwd-20230629_lab.xml" ] }, "presentationLink": { "local": [ "irwd-20230629_pre.xml" ] }, "schema": { "local": [ "irwd-20230629.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "irwd", "nsuri": "http://ironwoodpharma.com/20230629", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2320339d1_8k.htm", "contextRef": "From2023-06-29to2023-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://ironwoodpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2320339d1_8k.htm", "contextRef": "From2023-06-29to2023-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ironwoodpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-077076-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-077076-xbrl.zip M4$L#!!0 ( *^ WE89T6)A+P, +T+ 1 :7)W9"TR,#(S,#8R.2YX MI>WS M<#O!GD(JEA,U-W6+;SOZ#9'^A'R +@Z3X[1+GH>8G<0=5'WQOR%R@_IWP:^7 M[D'X_355X2>O_\B.CM^^1@^OW=1M77ZY'XVOV\'GVSQD0_HC'"*@+X/)IF7J M*\I+JC870Z?BNI[S?-/I93@K!]932MCK*KA7J]6\C'CG9H?*5: M F,)APA%$_ R7XF6CCFP%*H9: V+H*@>HNP7 G-77,$(I)@@B6"LX3S(!HA M$2+3F1G6/:K4]'Q1'&*FKK@(+_$ Q52G\S-&E P(#BR@D!AB95I-1LC'6VF6 M78L8X[JY]805%F.+(J*[5QO>-DV"_.4D.7RX4";&DT M-[V/^X7XFM8%B=K#D06."7@56/3N5P33379*8GL!N292\/9)8\TJOBB_7 MPK#B MK4_G3\QL+_=J I_'3(FW71IAEE)N]KN-Z5]]NXLH\?DEF!_]OF'WZ(+EX*M: MH.'D:GKY&U!+ P04 " "O@-Y6H4WVW?X* " A@ %0 &ER=V0M,C R M,S V,CE?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XW&"+9KL9!<93[(P-IND ML6>V[:)8T!+C")')@)(3^]^7E$19(GDD)45)SL6,1WP/]5)\3%)?QY]^W&U2 M]$)XEC!Z/IH>?1PA0B,6)W1]/OJZ&%\L9O/Y"&4YIC%.&27G(\I&/_[PQS\@ M\>?3G\9C=)60-#Y#7U@TGM,']CVZP1MRAGXBE'"<,_X]^H;3K=S"KI*4<#1C MF^>4Y$04E#L^0]\=3?^^0N/Q@'J_$1HS_O5^7M?[F.?/V=ED\OKZ>D39"WYE M_"D[BMAF6(6+'.?;K*[MX^YC]:<,_Y0F].E,_K7"&4'B>-'L;)9KO"+I"$FEX -LUVFKKBIHXMKL'>$)BR_I^USKT9[LB^\.S_^' M!C3CG3=AR7*6\HEN22HON/*% M>=33N$HQB9B8FI[S<5H>QC+\@;.-=;=5JYFE\/=T5<>7AT7L C#:DG&2L2V/ MR)MZI>D6.DJ5HTTJ%'))1>CXZV+T0Z%!ORG5?SY-#K4XZ&BQ!-IN",V7HD9+ M"]K%KKK99DKUB_7&B1%OKKY"\DBGCS+Y7Q7.UHRYYUN,6GT?4,3%@*F,9B$AM;3 MP'Y/UHF<6J0%>7Y+Y,:.80S0NQ[Z.VWKR+B'UMQQDYXNN^%PE"ZY@*P MJJ.AR8*BP^X-!*26^V5DR3'-$CF ]4)B2IV?;@!FC5,/31<4)X Y^)2DUOLE M9?%(TE3>#\"T?T"QB5W3 AO6>3&501$#V@.9*2)0%1(.-I6"43,'V6[5NZ>JPVV;*(@R()-@=P$^E_* ^(!F#;FDHT!R_H:G' M_J$Y'@K-<=#0'+\'FN4K"P2:DSTEH!"^9(;D7 M8 #35FHT;7CHV WV\5,OB%6U=T8T[0J=]R;O_(D%WN>L[G.DD5%K4%CO&8L'2)$KRA*Y_$2>?/,&V5ME$KH" M#2H:3$40*("V= X.0J24CB&XXT1"2$1'%"\!RL1"_/;AP3K;=XE=0=%O6,$! M*X. I->>#HL(&$>-"%2&H"+&+S;S+-L2_B9X+"&>$ +- R 9^A!Q@DSV0E4& M^F1K0:*MF!_WT^/5,LE3V\FE*7$V)P'FZAE)*P^"#<"4SD)1AM@#FA[_9?57 MI*(<=_\-6W(LD\"'!+G,]]-M,ZL-_ M4Q,$ AW&C).22HJ4UL<+"8Q8!ZQ 7 >NABX"UMT6 VFV9 M(D2,2[>K-%EC(#EAI]HU%!V6=3XLTJ!0@?V!8T8=@@XQKC-:%BG.9'I^OBGV M?R4^6%H)Z)SEM.RR62>UM(F"8*3+F9'6LDPZUQ CJ7;-Q39.9K<'KT83 TS*2!4QFFD;2[V%Y*Y?JNPRK;]-:=,&A%"G0?#]R3I&IHK!BBEO*6/X3"RUUJSC*7%-Y3YQ MC&'1S!U32P+"P^:K(X,,1TKKA87%!J?IYVV64)+!$Y&F7[\T$D7RA8AR54YCS&T(=8F=_^H(:-CX[1%#&01(O?;@ MWR&I(Y *<4S-K6"8-\_C"A/SG&S MQWZ0UP1--2\XJA/'P1- TWJ3!5A[9/K M(A#)2)_9C)K)[>$E7DOD>&5L,:@MC!N*(!@!;4'+XN9O!?C)G;==I4ETE3(, M7V5I:1QGS#/M:XM?@,!#%:A1QX?&C.7S8IY\:%QF@-L0C<SLNRU))]_6*8\>J9*,RDN6MVCXU9$12P3)J87K:^C M]N6H/QRV(FV(2 B7@EZTA&Q]^.O77R+[<_Y;NQT-&.7)6?11QNVAF,CWT2U) MZ5GTB0JJB)'J??2-\,P=D0/&J8KZ,IUS:JC]HFCX+'ISU'TWCMIM0+W?J$BD M^OHPW-0[,V:NSSJ=Q6)Q).0S64CUI(]BF<(J'!EB,KVI[7AYO/XIBI]S)I[. MW*\QT32RO(0^6VIVT7+MKIM=G!Q)->WTCH^[G7^^W(SB&4U)FPG'+::MLI2K MI:I<]_3TM)-_6YH>6"['BI=MG'1*=S8UVV]9P'[+$\W.=.[>C8R)R<->VTSD MM7#_M4NSMCO4[O;:)]VCI4Y:)?RV6UI_\\(S12<7+:86B6VC=W+\MG?J6OA]Q\BLYK9[:N9Z5ROJ[+0^ M5U1387+!-_; 3A&Z-+93T:2LR+7_,O\,,Z[(NN-TH[;K95EJ6[0?"\NU.Z5# M7,8[/G 7#;DGN.S9.7--XZ.I?.XDE'4Z)0Y?YTK[M)+W<'PN. I @1_ M@CE2!-4B1>!2B(SP!SJ7J@;\KB60]Q^8O*NT(6'^.R/*4,57$-('QD#8;S!A M>Q0B\7Y41&CF^$" 'UH#B;]%O?'P:$1"/II1SETZ1P2HEU?9 ['_B8G=K_,5 M@+]^=M=W>VF!L]\J L3_[K7@/U"+%(%[JIA,["5= =@?& .IGV)2]RA$Y7TM M$BCMC2DX_\&'O2/0%@H;);,,"T2A_4B6P\2J8A-63 S60_<6@;)' M22M!% R3=?(!TE*)=)8G'I]9\; M)F@W%(I*<_ <$5X C)?"?;>R[#WX-A1\M!:F:\$^\G+L)_ L:/DHK4R,;'W M[<<[]2@7GAEHKS$4.4HN6B,1$WA^I;E3]TH^LV)]5!WU@Q)0](@I:E@L:HON)*OMH0T*8?,!9Q=P\M?$N) M]DR@?%%RU4HY32-U$5:4^+OOK@44*$H"6B6F89XWTLU]S*0(/H\]M()R1

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end